Interactome Biotherapeutics Inc Press Releases

• Published on March 25, 2025 - 14:00 GMT

  Interactome Biotherapeutics Announces Exclusive Global Option Agreement & Partnership with Oxford University Innovation

  Partnership to accelerate development of Novel Small Extracellular Vesicle CNS Drug Delivery Platform and enhance Interactome Biotherapeutics' Pipeline OXFORD , UNITED KINGDOM, March 25, 2025 /⁨EINPresswire.com⁩/ -- Interactome Biotherapeutics, a West …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on March 18, 2025 - 14:00 GMT

  Interactome Biotherapeutics Accepted into MassBio Drive Spring Cohort

  CAMBRIDGE, MA, UNITED STATES, March 18, 2025 /⁨EINPresswire.com⁩/ -- Interactome Biotherapeutics, a pioneering biotechnology company focused on Engineered small Extracellular Vesicle Biotherapeutics for Diseases of the Central Nervous System, is proud to …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on December 10, 2024 - 15:00 GMT

  Interactome Biotherapeutics Forms Scientific Advisory Board for Development of Nerve Injury-Focused EV Therapeutic IB001

  KALAMAZOO, MI, UNITED STATES, December 10, 2024 /⁨EINPresswire.com⁩/ -- Interactome Biotherapeutics, a biotechnology company dedicated to advancing Extracellular Vesicle Therapeutics, is thrilled to announce the appointment of a distinguished group of …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on October 16, 2024 - 14:30 GMT

  Interactome Biotherapeutics enters Exclusive License Agreement with Henry Ford Health to Advance sEV-Based Therapies

  Preclinical research indicates small Extracellular Vesicles (sEV) have therapeutic potential for Neurological, Cardiovascular, and Cancer Treatments DETROIT, MI, UNITED STATES, October 16, 2024 /⁨EINPresswire.com⁩/ -- Interactome Biotherapeutics Inc. (IB …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...